Data as of Jul 25
| -0.03 / -0.30%|
The 3 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 15.00, with a high estimate of 16.00 and a low estimate of 15.00. The median estimate represents a +50.45% increase from the last price of 9.97.
The current consensus among 3 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.